Jubilant Pharmova Ltd
Jubilant Pharmova Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹1,752Cr
- +4.3% YoY
- Net profit
- ₹102Cr
- +64.5% YoY
- Margin
- 17%
- +3 pp YoY
Guidance rank: #70 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jubilant Pharmova Ltd Q2 FY25 key numbers
- Revenue
- Q2’FY25 total income grew 5% YoY to Rs. 1,774 Cr.
As stated in Jubilant Pharmova Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Jubilant Pharmova Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2’FY25 total income grew 5% YoY to Rs. 1,774 Cr. EBITDA: Rs. 311 Cr. in Q2’FY25, up 19% YoY from Rs. 261 Cr. in Q2’FY24.
From Jubilant Pharmova Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane Sterile Injectables Capacity Expansion:
- Doubling capacity of sterile fill and finish (liquid and lyophilization).
- Total investment: USD 285 million (including USD 149.6 million US Govt funding).
- Technology transfer started for Line 3.
- FDA approval application planned for FY26.
- Commercial production expected post approval in FY26/FY27.
- Estimated incremental revenue potential: USD 160–180 million.
- Aim to fill capacity faster than industry average (3-4 years typical).
- Montreal Facility:
- Undergoing corrective and preventive actions (CAPA) post USFDA observations.
- Expected to restart operations mid Q3 FY25.
- Generics Roorkee Facility:
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,752 | 1,680 | +4.3% | 1,732 | +1.2% |
| Operating profit (EBITDA) | 289 | 242 | +19.4% | 252 | +14.7% |
| Operating margin | 17% | 14% | +3 pp | 15% | +2 pp |
| Profit before tax | 144 | 98 | +46.9% | 500 | -71.2% |
| Net profit (PAT) | 102 | 62 | +64.5% | 482 | -78.8% |
| EPS (₹) | 6.45 | 3.92 | +64.5% | 30.26 | -78.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Themis Medicare (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q2 FY25 results?
Q2’FY25 total income grew 5% YoY to Rs. 1,774 Cr. EBITDA: Rs. 311 Cr. in Q2’FY25, up 19% YoY from Rs. 261 Cr. in Q2’FY24.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane Sterile Injectables Capacity Expansion: - Doubling capacity of sterile fill and finish (liquid and lyophilization).
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.